CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
Elotuzumab +2 moredrug
Likely dose
Elotuzumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02279394
NCT02279394Phase 2Completed
CompareCT.gov

E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted Oct 31, 2014·Updated Jun 9, 2023

In Brief

A Phase 2 clinical trial evaluating Elotuzumab, Lenalidomide, and 1 other intervention for Smoldering Myeloma and Smoldering Multiple Myeloma. Completed, enrolled 51 participants across 9 sites.

Detailed Summary

This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoldering Myeloma, Smoldering Multiple Myeloma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Celgene, Blood Cancer Research Partnership, Multiple Myeloma Research Consortium, The Leukemia and Lymphoma Society

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 31, 2014
Enrollment StartDec 11, 2014
Primary CompletionDec 12, 2018
Study CompletionJan 26, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 11.7 years ago

Interventions

Elotuzumabdrug

10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8

Lenalidomidedrug

25 mg Oral; Days 1-21 days Cycles 1-24

Dexamethasonedrug

40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8